The document details the significant growth and development of the pharmaceutical sector in Bangladesh, highlighting that 97% of the market's needs are met by local manufacturers. Incepta Pharmaceuticals is showcased as a leading and innovative company in this sector, having launched numerous first-ever generics and products while becoming a top ranked company. The company has also expanded internationally, registered products in various countries, and maintained a strong growth trajectory since its establishment in 1999.

1. Bangladesh
&
Pharma Market
Prepared By:
Biplob Kumar Sarker,
Product Executive, PMD,
Medicon Pharmaceuticals Ltd.

2.  The pharmaceutical sector is highly
developed in Bangladesh and contributes
significantly to the country's economy.
 97% need of Bangladesh Pharma market is
fulfilled by their own manufacturers.
 Among the Bangladeshi
pharmaceuticals, some company is improving
day by day in a aggressive manner & some
are going with average business.

3. 1. Square Pharmaceuticals Ltd.
2. Incepta Pharmaceuticals Ltd.
3. Beximco Pharmaceuticals Ltd.
4. Opsonin Pharma Ltd.
5. Eskayef Bangladesh Ltd..

4. A symbol of improvement

5.  Incepta Pharmaceuticals is a very first
growing pharmaceuticals of Banngladesh.
 Incepta Pharmaceuticals Ltd. is a leading
pharmaceutical company in Bangladesh
established in the year 1999.
 The history of this company is very much
attractive and impressive.

7.  December 16th 1998, the construction of the factory began.
 August 1999, office operations began.
 December 1999, first batch of product Neodin S 150 (Ranitidine 150
mg tablet) was produced.
 January 2000, sales began formally.
 February 2000, training of the first batch of medical representatives
began.
 April 2000, with the launching of Osartil (Losartan Potassium) the
first prescription product of Incepta was launched in the market. The
company started off in a new direction.
 Several other first ever product, Celenta (Celecoxib), Rofenta
(Rofecoxib) and Omidon (Domperidone) followed in the footsteps of
Osartil.
 A total of 23 new generics with 35 presentations were launched this
year. 4 of these generics were first ever in Bangladesh.
 By the end of 2000 Incepta was the number 31st company of the
country.

8.  There was massive restructuring throughout
the company. Sales, Distribution, Marketing
Strategy Department, and Factory; all were
reorganized.
 A total of 18 new generics with 37
presentations were launched this year. 11 of
these generics were first ever in Bangladesh.
 By the end of the year Incepta was ranked
the 12th company of the country. The
company had a phenomenal growth of 448%
over the previous year (IMS).

9.  A total of 32 new generics with 49
presentations were launched. 14 of these
generics were first ever in Bangladesh.
 Massive expansion project of the factory was
envisioned. New office for the sales and
distribution operation was also taking shape.
 The company registered an excellent growth
of 55.85% over the previous year. By the end
of the year Incepta was ranked the 10th
company of the country (IMS).

10.  Incepta kept on introducing innovative and
newer molecules to the local market. A total of
32 new generics with 48 presentations were
launched. 18 of these generics were first ever
in Bangladesh.
 The new office (Dhanmondi) for the sales and
distribution operation was inaugurated.
 The company registered an excellent growth
of 28.5% over the previous year (IMS).
 By the end of the year Incepta was ranked
the 8th company of the country (IMS).

11.  A total of 17 new generics with 32
presentations have been launched. 6 of these
generics were first ever in Bangladesh.
 The company maintained an excellent growth
of 48.2% over the previous year (IMS).
 The ranking went up again and the company
was ranked the 5th largest company of the
country with the highest growth rate among
the top five (IMS).

12.  We thrived under challenge and excelled in
venturing into unexplored grounds and continued
to satisfy our customers. Incepta was audited and
accepted as a supplier for UNICEF & UNDP. We
started to supply life saving drugs to UNICEF from
March, 2005.
 A total of 27 new generics with 76 presentations
were launched. 12 of these generics were
introduced first time ever in Bangladesh.
 The company maintained an excellent growth of
34.8% over the previous year (IMS).
 The company was ranked 3rd largest with the
highest growth among the top five (IMS).

13.  By 2006 Incepta had positioned itself as an innovative
research oriented and knowledge based
pharmaceutical company specializing in analysis,
design and development of new products.
 Incepta successfully started overseas marketing
operation from May 2006.
 A total of 25 new generics with 82 presentations were
launched. 9 of these generics were first ever in
Bangladesh.
 The company maintained an excellent growth of
31.26% over the previous year (IMS).
 The company maintained the ranking of 3rd largest
(IMS).

14.  Incepta pioneered the introduction of biotech products (Human
Insulin) and lyophilized products (Pantoprazole injection) in the
Bangladesh pharmaceutical market. This was the first time a local
pharmaceutical company produced such highly sophisticated
technology product in the country.
 A total of 32 new generics with 82 presentations were launched. 4 of
these generics were first ever in Bangladesh.
 Marketing, Sales, Distribution and Administration departments
shifted to the fully owned new office premises in Tejgaon, Dhaka.
The international standard head office of Incepta started operation in
the new office premises on 1st October, 2007.
 A marketing and sales team was setup in Myanmar headed by a
country manager from the Marketing Strategy Team to promote the
35 products registered with the Myanmar FDA.
 The company maintained a growth of 12.93% over the previous year
(IMS).
 The company held the 3rd largest ranking (IMS) among the
companies.

15.  Continued investment in our core strength that is our manufacturing plant led to recognition
from European authorities and on January 11, 2008 Incepta attained European "Certificate
of GMP Compliance".
 40 new products with 86 presentations were introduced of which 10 were first ever in
Bangladesh.
 The plant received GMP certification (General formulations and Cephalosporins) from
Kenyan Ministry of Health on January 21, 2008.
 Incepta was also awarded GMP (Cephalosporins) from Ethiopian Ministry of Health on July
22, 2008.
 Incepta registered 51 products in Mongolia on September 26, 2008 (As first Bangladeshi
Company).
 Incepta registered 3 products in Georgia on October 13, 2008 (As first Bangladeshi
Company).
 In 2008 significant number of products got registration in different countries. 19 products
from Democratic Republic of Congo, 20 products from Sri Lanka, 22 products from Togo, 8
products from Hong Kong, 20 products from Mauritania, 6 products from Vietnam, 1 product
in Cambodia.
 The company maintained a growth of 12.10% over the previous year (IMS).
 The company became the 2nd largest (IMS) among the companies operating in
Bangladesh.

16.  Incepta started venturing in the field of human vaccines and
hormonal products. Construction of the Vaccine & Hormones
facilities started on 1st January 2009 and 8th November 2009
respectively.
 Incepta became the first Bangladeshi Company to get GMP
Compliance Certificate from Turkey (Tablets, Capsules and
Lyophilized products) on January 08, 2009.
 Incepta achieved GMP certification from the Ministry of Health,
Yemen on May 25, 2009 (Sterile and Non-sterile products).
 Incepta launched 51 new products in 2009. 4 of these were
first ever in Bangladesh pharmaceutical market.
 The company maintained an excellent growth of 27.71% over
the previous year (IMS).
 The company maintained the 2nd largest (IMS) position in
2009.

17.  Incepta was accepted and became enlisted with the
Copenhagen office of UNICEF, UNDP and UNESCO
as global supplier of medicine.
 Incepta was awarded GMP certificate from Uganda,
National Drug Authority on 5th August 2010 (Sterile
Products, Non-sterile products and Cephalosporins).
 Incepta launched 56 product presentations. 10 of
which were first ever in Bangladesh market.
 Incepta maintained the 2nd largest (IMS) position in
Bangladesh pharmaceutical market in 2010. The
company showed the strongest growth among the top
10 companies with a growth rate of 34.97% (IMS).

18.  Incepta introduced Human Vaccines to the market and
become the first Bangladeshi vaccine manufacturing
company.
 Export has emerged as a focus area for Incepta. With
over 300 products registered in different countries
export is now set to play more important role in the
growth of the company. Currently the company exports
to 37 countries of the world with many more in the
pipeline.
 Since starting supply of medicine to UNICEF in
Bangladesh, Incepta has remained the largest supplier
till today.
 In 2011 the company has launched 55 products, 9 of
which are first ever in Bangladesh market.

19. In 2012 the company has launched 52
products, 7 of which are first ever in
Bangladesh market.

20. Up to March, 2013, the company has
launched 21 products, 4 of which are first
ever in Bangladesh market.

25. Reference:
1. http://www.inceptapharma.com
2. http://archive.thedailystar.net/newDesign/
news-details.php?nid=239204